What do you recommend for this patient with COPD? CHEST Physician 3/2024

What do you recommend for this patient with COPD? CHEST Physician 3/2024

Article by Jerry A. Krishnan, MD,PHD, Muhammad Adrish, MD, FCCP

Waiting for Actionable Evidence: Roflumilast or Azithromycin? 11/2021

Waiting for Actionable Evidence: Roflumilast or Azithromycin? 11/2021

Letter to the Editor of the Journal of the COPD Foundation
Jerry A. Krishnan, MD, PhD1 Richard K. Albert, MD2 Stephen I. Rennard, MD3 on behalf of the RELIANCE study

Poster presented at ATS 2019

Poster presented at ATS 2019

Documentation in electronic health records is insufficient in 20 to 40% of patients with COPD to support screening activities for a multi-center clinical effectiveness trial comparing roflumilast and azithromycin therapy.

Selected literature related to RELIANCE, updated May 2019

Selected literature related to RELIANCE, updated May 2019

Selected literature related to the RELIANCE Clinical Trial, May 2019

Medication comparison poster for clinicians

Medication comparison poster for clinicians

Summary of harms and benefits of Roflumilast and Azithromycin

Prescribing information for Roflumilast, updated 1/2018

Prescribing information for Roflumilast, updated 1/2018

FDA prescribing recommendations for Roflumilast, updated 2018

1 2 3 4 5 6
Previous Next
What do you recommend for this patient with COPD? CHEST Physician 3/2024
Waiting for Actionable Evidence: Roflumilast or Azithromycin? 11/2021
Poster presented at ATS 2019
Selected literature related to RELIANCE, updated May 2019
Medication comparison poster for clinicians
Prescribing information for Roflumilast, updated 1/2018